Iza-bren improved survival and delayed disease progression versus chemotherapy in previously treated metastatic ...
MedPage Today on MSN
Investigational ADC Ups Survival in Advanced Triple-Negative Breast Cancer
Izalontamab brengitecan more than doubled PFS compared with chemotherapy ...
SurvivorNet on MSN
For triple-negative breast cancer patients without immunotherapy options, FDA approval of Datroway brings hope by helping patients live longer
The FDA has approved Datroway (datopotamab deruxtecan) for adults with unresectable or metastatic triple‑negative breast ...
Izalontamab brengitecan extends overall survival among patients with metastatic TNBC, but it’s unclear how the ...
The Food and Drug Administration (FDA) on May 22, 2026, approved Datroway (datopotamab deruxtecan-dlnk) for adult patients ...
March 28, 2007 — A new study clearly reveals the survival disadvantage for the so-called "triple-negative" subtype of breast cancer compared with other types of breast cancer. These tumors test ...
MedPage Today on MSN
New first-line option approved in triple-negative breast cancer
Datopotamab deruxtecan indicated for patients ineligible for immunotherapy ...
A new study found that breast cancer deaths are increasingly affecting younger women, while survival rates have improved ...
Breast cancer deaths, once concentrated mostly among older women, are now claiming younger women more often, researchers ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results